DANAHER CORP /DE/ (DHR) stock intrinsic value fair value estimate & owner earnings analysis

Danaher is a life-sciences and diagnostics company run on the Danaher Business System, a continuous-improvement discipline applied to businesses it buys. Its main franchises are bioprocessing equipment and consumables (Cytiva, Pall, Aldevron, Abcam) used to make biologic drugs, clinical diagnostics (Beckman Coulter, Radiometer, Cepheid, Leica Biosystems), and life-science instruments (SCIEX, Molecular Devices, IDT). A large share of revenue is recurring consumables, reagents and service tied to an installed base, and many of the products are written into regulated drug and test procedures, which makes customers slow to switch. The company is smaller than it was: Fortive (2016), Envista (2019) and Veralto (September 2023) were spun off, so results before late 2023 describe a different, larger company, and 2021-2022 were also lifted by an unusual surge in COVID-19 molecular testing. We therefore judge the current business from 2023 onward. WHAT THE BUSINESS EARNS. We measure cash earnings after stock compensation and after the capital spending needed to stay in business, with swings in receivables, inventory and payables removed. Excluding Veralto, that came to about $6.5 billion in 2021 and $7.1 billion in 2022 (COVID testing peak), then $4.1 billion in 2023 (bioprocessing customers working off excess inventory), $4.7 billion in 2024 and $5.3 billion in 2025. That is $5.47, $6.41 and $7.37 per diluted share for 2023, 2024 and 2025. Danaher's cash from operations includes a very large add-back of roughly $1.7 billion a year of non-cash amortization of acquired intangibles; we accept that add-back because the acquisition cost is already spent, but acquired technology and customer relationships do wear out, so we carry that wearing-out in the growth path and the bear case rather than lowering today's earnings. We also add back about $0.3-0.4 billion a year of interest paid to measure what the business produces before its lenders, and subtract the debt afterward. The 2023-2025 median of this pre-interest business cash flow is about $5.1 billion, roughly $7.20 per share on today's 707.6 million diluted shares, and that is the level we start from. 2025 is not used as the starting level because capital spending was 17% lower than in 2024 ($1.16 billion versus $1.39 billion) and swings like that reverse. GROWTH CHECK. Owner earnings per share grew about 15% in 2025 (from $6.41 to $7.37) and business cash flow grew about 10%. We assume only 3% in the first year, below what was just achieved, so no reversal needs to be explained. The first half of 2026 is consistent: operating cash flow rose to $2.86 billion from $2.64 billion, revenue grew about 4.6% to $12.2 billion, and capital spending was steady at $506 million. WHAT CHANGED SINCE THE LAST ANALYSIS. In 2026 Danaher paid about $9.8 billion in cash to acquire Masimo (pulse oximetry and patient monitoring; about $1.5 billion of 2025 revenue), funded with debt and cash. Long-term debt rose from $18.4 billion at year-end 2025 to $26.6 billion at June 2026 while cash fell to $4.3 billion. That purchase is a real addition to what the company owes, and the Masimo business earns far less than its price: its own filings show operating cash flow of $218 million in 2025 and $196 million in 2024, and after stock compensation ($36 million) and capital spending ($19 million) that is roughly $160 million a year. We credit about $150 million a year, with no synergies; Danaher's savings targets are not counted because they have not happened. Our previous figures were prepared on a different basis and are not comparable, so we do not line them up against these. The earnings series itself has also been rebuilt for the continuing company only: earlier figures for 2021-2023 included cash flows from the Veralto businesses that left in 2023. WHAT THE COMPANY OWES. Total borrowings are $26.6 billion against $4.3 billion of cash, a net $22.2 billion. Most of the older notes carry very low fixed coupons (for example 0.2%-1.35% on euro and yen notes due 2026-2039, 2.6%-3.4% on US notes due 2029-2051, only 4.375% on the 2045 notes), with maturities spread out to 2051 and interest paid of only $331 million in 2025. Paying lenders well below market rates for many years is worth a reduction of about $3.5 billion in the debt figure, which we apply, giving about $18.7 billion, or $26 per share. In every case below, business cash flow comfortably covers interest, and no near-term maturity is a problem for a company with this record of cash generation; the 2026 notes (EUR 1.3 billion and EUR 800 million) and 2027 notes are small against $5 billion-plus of annual cash flow. BASE CASE ($100.80 per share). Business cash flow starts at the $5.1 billion median plus $150 million from Masimo and grows 3% a year for ten years. That growth rests on named evidence: the recurring consumables, reagent and service base kept earning through the 2023 destocking and the post-COVID testing drop, revenue has recovered since 2023 ($23.9 billion to $24.6 billion in 2025, plus about 4.6% in the first half of 2026), and pricing and productivity under the Danaher Business System have a decades-long record. We stop at 3% because larger growth would need market expansion, share gains, new products or margin expansion, which we do not credit. Cash flow is then held flat for another twenty years (to year 30) because the regulated, installed-base nature of the products is a structural feature already in evidence, and nothing evidences it beyond that. The business is worth about $127 per share, it owes about $26, leaving about $101. Serial acquisition is not credited as growth: the deals (Cytiva at $21 billion, Aldevron, Abcam, Masimo) are large single bets, not small steady increments, and the company wrote off $562 million of assets in 2025 and $265 million in 2024. BEAR CASE ($45.00 per share). The bear case includes a full downturn of the 2022-2023 kind: business cash flow fell from about $7.5 billion in 2022 to $4.5 billion in 2023 as testing revenue unwound and bioprocessing customers destocked. We apply a second slump of similar depth on top of today's starting level: 30% below the median for two years, 20% below for two more, 10% below for two years, then 5% below and eroding 1% a year as acquired technology ages and impairments recur ($562 million in 2025), with the story ending after year 20. Masimo adds nothing, so the entire $9.8 billion is lost value. The business is worth about $71.50 per share, it owes about $26.40, leaving about $45. Even at the trough, cash flow of about $3.6 billion is well above the interest bill, so the debt can be carried. BULL CASE ($145.80 per share). The company's own levers execute: cash flow starts at the 2025 level ($5.6 billion, reached under current conditions) plus Masimo at its 2025 level ($163 million), then grows 5% a year for ten years, in line with the roughly 4.6-5.5% revenue growth already printing in 2026 and Masimo's 9% growth in 2025, and is then held flat to year 35. The business is worth about $172 per share, it owes about $26.40, leaving about $146. WHAT WOULD MAKE THIS WRONG. The most important assumptions are that the 2023 destocking low was a trough rather than a new normal (the first-half 2026 operating cash flow gain of about 8% supports this), that Masimo earns at least what it earned before the purchase (it faces a long history of patent litigation and a 2022 operating cash flow of only $29 million shows how volatile it can be), and that the installed-base and consumables model keeps its pricing. A second year of falling bioprocessing orders, tariffs or China pricing reforms, or further write-offs, would push results toward the bear case. MARGIN-OF-SAFETY PRICE ($52 per share). We are fairly sure of the earnings level because 85% or so of the business is recurring and three separate years, 2023-2025, bracket it, but not sure about growth, and the recent $9.8 billion purchase adds a new uncertainty. The worst plausible outcome is a repeat of the 2023 slump combined with Masimo failing to earn anything: the bear case, about $45. Danaher's balance sheet would survive that, because even the bear cash flow is several times the interest bill and the notes are cheap and long-dated. If we are wrong on the two things most likely to be wrong, the starting level (a 2023-like year being the new normal would take the value to about the low $90s on the base path) or the growth rate (flat instead of 3% takes the value to about the low $80s), the shares are still worth more than $52, so that price can absorb one of those errors, but not both. The price assumes a four-to-five-year holding period. During that period the business pays about $1.40 a year in dividends and produces roughly $6.50 per share of owner earnings after interest, around 12% of a $52 price, and that cash is retained to buy back stock and pay down debt. The margin-of-safety price is $52 because, from that price, the cash the business generates plus ordinary growth would carry most of a 20% annual return in the base case and the rest would come from the shares moving toward the value of the business over four to five years, while the bear case implies a decline of under 15%.